PDB81 - DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.786
https://www.valueinhealthjournal.com/article/S1098-3015(18)34086-5/fulltext
Section Title :
Section Order :
191
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34086-5&doi=10.1016/j.jval.2018.09.786